393 related articles for article (PubMed ID: 31338108)
1. Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease.
Kim GH
Electrolyte Blood Press; 2019 Jun; 17(1):1-6. PubMed ID: 31338108
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.
Beccari MV; Meaney CJ
Core Evid; 2017; 12():11-24. PubMed ID: 28356904
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.
Dong L; Xu W; Deng Y; Tan J; Qin W
Eur J Pharmacol; 2022 Sep; 931():175174. PubMed ID: 35964658
[TBL] [Abstract][Full Text] [Related]
4. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
5. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
[TBL] [Abstract][Full Text] [Related]
6. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
Georgianos PI; Agarwal R
Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
[TBL] [Abstract][Full Text] [Related]
7. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
9. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
[TBL] [Abstract][Full Text] [Related]
10. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
11. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
12. Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.
Linder KE; Krawczynski MA; Laskey D
Pharmacotherapy; 2016 Aug; 36(8):923-33. PubMed ID: 27393581
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.
Gruver J; Al-Makki A; Shepler B
J Pharm Pharm Sci; 2023; 26():11892. PubMed ID: 38173862
[TBL] [Abstract][Full Text] [Related]
14. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
Athyros VG; Sachinidis AG; Zografou I; Simoulidou E; Piperidou A; Stavropoulos N; Karagiannis A
Curr Pharm Des; 2018; 24(46):5542-5547. PubMed ID: 30848186
[TBL] [Abstract][Full Text] [Related]
15. Managing Hyperkalemia: Stepping Into a New Frontier.
Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
[TBL] [Abstract][Full Text] [Related]
16. Prescription patterns of sodium and calcium polystyrene sulfonate in patients with hyperkalemia and chronic kidney disease receiving RAAS inhibitors.
Ren H; Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Collister D; Tangri N
Clin Kidney J; 2022 Sep; 15(9):1713-1719. PubMed ID: 36003673
[TBL] [Abstract][Full Text] [Related]
17. Hyperkalaemia and potassium binders: Retrospective observational analysis looking at the efficacy and cost effectiveness of calcium polystyrene sulfonate and sodium zirconium cyclosilicate.
Huda AB; Langford C; Lake J; Langford N
J Clin Pharm Ther; 2022 Dec; 47(12):2170-2175. PubMed ID: 36114759
[TBL] [Abstract][Full Text] [Related]
18. Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease.
Nakayama T; Yamaguchi S; Hayashi K; Uchiyama K; Tajima T; Azegami T; Morimoto K; Yoshida T; Yoshino J; Monkawa T; Kanda T; Itoh H
Front Med (Lausanne); 2023; 10():1137981. PubMed ID: 36950508
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches to management of hyperkalaemia in kidney transplantation.
Rizk J; Quan D; Gabardi S; Rizk Y; Kalantar-Zadeh K
Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):27-37. PubMed ID: 33027094
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
Meaney CJ; Beccari MV; Yang Y; Zhao J
Pharmacotherapy; 2017 Apr; 37(4):401-411. PubMed ID: 28122118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
